News

WuXi News

Filter By

2021/09/05

WuXi AppTec Receives AA ESG Rating from MSCI

Shanghai, September 5, 2021 – WuXi AppTec (“the Company”) is pleased to announce that Morgan Stanley Capital International ("MSCI”) has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of “corporate governance” and “product safety and quality”. This new rating reflects WuXi AppTec’s commitment to incorporating environmental and social responsibilities into the company’s business strategies and operations.

Read more

2021/08/12

WuXi AppTec Reports Strong 2021 Interim Results

Revenue Up 45.7% Year-Over-Year to RMB10,537 Million Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 67.8% Year-Over-Year to RMB2,448 Million Adjusted Non-IFRS Diluted EPS Up 58.5% Year-Over-Year to RMB0.84

Read more

2021/08/03

WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

State-of-the-art facility significantly enhances WuXi STA's drug product capacity in Europe while better enabling global customers

Read more

2021/06/28

WuXi STA Chooses Middletown Delaware for New Pharmaceutical Manufacturing Campus

WILMINGTON, Del. (June 28, 2021) — WuXi STA and Delaware Prosperity Partnership today announced that WuXi STA, a leading Contract Development and Manufacturing Organization (CDMO), will build a new pharmaceutical manufacturing campus in Middletown, Delaware. The state-of-the-art WuXi STA Middletown Site, which is expected to open in 2024 and be its first on the East Coast, will be located at 1091 Industrial Drive in Middletown Business Center and aims to bring about 500 new full-time jobs to Delaware by 2026.

Read more

2021/04/29

WuXi AppTec Reports Record First-Quarter 2021 Results

(SHANGHAI, April 29, 2021) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter of 2021 (“Reporting Period”).

Read more